Form 4: Dianthus Therapeutics Director Steven J. Romano Acquires 22,000 Stock Options

Director Steven J. Romano acquired 22,000 stock options in Dianthus Therapeutics on September 16, 2024, according to a Form 4 filing.

Summary

• Steven J. Romano, a director of Dianthus Therapeutics, acquired 22,000 stock options on September 16, 2024.
• The exercise price of these options is $26.42.
• The options vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service to Dianthus Therapeutics.
• The options expire on September 15, 2034.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, and the acquisition of stock options by a director is neither particularly positive nor negative on its own. It suggests continued alignment of the director's interests with the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the actions of company directors and officers.

Stakeholder Impact

• The acquisition of stock options aligns the director's interests with those of the shareholders, as the value of the options increases with the company's stock price.

Key Dates